Yüklüyor......
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. Aβ capture by these clinical antibodies is explained here with the...
Kaydedildi:
| Yayımlandı: | Sci Rep |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549621/ https://ncbi.nlm.nih.gov/pubmed/25880481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep09649 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|